Zacks Investment Research lowered shares of Strongbridge Biopharma (NASDAQ:SBBP) from a hold rating to a sell rating in a research report report published on Wednesday morning.

According to Zacks, “Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing’s syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. “

A number of other equities research analysts have also recently issued reports on the company. Cantor Fitzgerald set a $17.00 price objective on Strongbridge Biopharma and gave the company a buy rating in a research note on Tuesday, October 2nd. Janney Montgomery Scott boosted their price objective on Strongbridge Biopharma to $16.00 and gave the company a buy rating in a research note on Wednesday, August 8th. BidaskClub cut Strongbridge Biopharma from a sell rating to a strong sell rating in a research note on Wednesday, September 5th. ValuEngine upgraded Strongbridge Biopharma from a hold rating to a buy rating in a research note on Thursday, November 1st. Finally, JMP Securities boosted their price objective on Strongbridge Biopharma from $10.00 to $16.00 and gave the company a market outperform rating in a research note on Thursday, August 9th. Two investment analysts have rated the stock with a sell rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and an average target price of $14.75.

Shares of NASDAQ SBBP traded down $0.01 during mid-day trading on Wednesday, reaching $5.82. 130,521 shares of the company’s stock were exchanged, compared to its average volume of 892,593. The stock has a market capitalization of $275.12 million, a price-to-earnings ratio of -4.01 and a beta of -0.36. Strongbridge Biopharma has a 52 week low of $3.85 and a 52 week high of $9.25. The company has a debt-to-equity ratio of 8.76, a current ratio of 3.38 and a quick ratio of 3.11.

Strongbridge Biopharma (NASDAQ:SBBP) last announced its quarterly earnings data on Wednesday, October 31st. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.38) by ($0.06). The company had revenue of $5.35 million during the quarter, compared to analyst estimates of $5.48 million. Research analysts expect that Strongbridge Biopharma will post -1.89 EPS for the current fiscal year.

A number of institutional investors have recently made changes to their positions in SBBP. Millennium Management LLC raised its stake in Strongbridge Biopharma by 380.4% in the 2nd quarter. Millennium Management LLC now owns 662,419 shares of the biotechnology company’s stock valued at $3,975,000 after acquiring an additional 524,539 shares during the period. BlackRock Inc. grew its holdings in Strongbridge Biopharma by 25.4% during the 1st quarter. BlackRock Inc. now owns 1,795,693 shares of the biotechnology company’s stock valued at $15,892,000 after buying an additional 363,328 shares in the last quarter. Opaleye Management Inc. grew its holdings in Strongbridge Biopharma by 15.1% during the 2nd quarter. Opaleye Management Inc. now owns 1,830,000 shares of the biotechnology company’s stock valued at $10,980,000 after buying an additional 240,000 shares in the last quarter. Intrinsic Edge Capital Management LLC purchased a new position in Strongbridge Biopharma during the 2nd quarter valued at about $1,200,000. Finally, Essex Investment Management Co. LLC grew its holdings in Strongbridge Biopharma by 62.9% during the 3rd quarter. Essex Investment Management Co. LLC now owns 434,161 shares of the biotechnology company’s stock valued at $2,106,000 after buying an additional 167,608 shares in the last quarter. Institutional investors and hedge funds own 67.30% of the company’s stock.

About Strongbridge Biopharma

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada.

Recommended Story: Dow Jones Industrial Average (DJIA)

Get a free copy of the Zacks research report on Strongbridge Biopharma (SBBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.